The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Brand Name :
Devrom
Synonyms :
bismuth subgallate
Class :
Gastrointestinal Agents
Dosage Forms & StrengthsÂ
TabletÂ
200 mgÂ
Swallow or chew 200 to 400 mg orally three times daily with food
Dosage Forms & StrengthsÂ
TabletÂ
200 mgÂ
Swallow or chew 200 mg orally three times daily with food
Refer to adult dosingÂ
bismuth subgallate: they may decrease the therapeutic effect of antacids
bismuth subgallate: they may decrease the therapeutic effect of antacids
bismuth subgallate: they may decrease the therapeutic effect of antacids
bismuth subgallate: they may decrease the therapeutic effect of antacids
bismuth subgallate: they may decrease the therapeutic effect of antacids
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
may decrease the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
decamethonium may amplify bismuth subgallate's neurotoxic effects
bismuth subgallate: it may decrease the excretion rate of isepamicin
bismuth subgallate may decrease the excretion rate of almasilate, leading to higher serum levels
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
it may decrease the levels of serum concentration of Fosfomycin
it may decrease the levels of serum concentration of Sirolimus
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may diminish the therapeutic effect
may decrease the therapeutic effect
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of Anticholinergic Agents
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may decrease the therapeutic effect of Opioid Agonists
buprenorphine,long-acting injectionÂ
may decrease the therapeutic effect of Opioid Agonists
acetaminophen/doxylamine/dextromethorphanÂ
may decrease the therapeutic effect of anticholinergic Agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
ceforanide: it may decrease the excretion rate of bismuth subgallate
Actions and SpectrumÂ
The digestive tract can absorb fluids and poisons thanks to the absorbent characteristics of bismuth subgallate. In situations of diarrhea, this activity helps to lessen the frequency and liquidness of feces.Â
bismuth subgallate forms a protective layer over irritated or injured mucous membranes, such as in the gastrointestinal tract. bismuth subgallate acts locally within the gastrointestinal tract and is not absorbed significantly into the bloodstream.Â
Frequency not defined Â
Temporary dark or black stool discolorationÂ
Temporary darkening of tongueÂ
Black Box WarningÂ
None
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:    Â
Pregnancy category: CÂ
Lactation: Drug is poorly absorbed into system circulationÂ
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
<b>Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
The mechanism of action of bismuth subgallate is not known. Â
PharmacodynamicsÂ
bismuth subgallate forms a protective layer over irritated or injured mucous membranes. Â
bismuth subgallate possesses deodorizing properties. It is used to help reduce or eliminate unpleasant odors associated with certain medical conditions, such as fecal or wound odors.Â
PharmacokineticsÂ
Absorption  Â
bismuth subgallate is poorly absorbed from the gastrointestinal tract. Â
DistributionÂ
bismuth subgallate does not exhibit significant distribution throughout the body.  Â
MetabolismÂ
bismuth subgallate is not extensively metabolized in the body. Â
Elimination and excretionÂ
bismuth subgallate is not significantly eliminated through urine.Â
AdministrationÂ
bismuth subgallate is typically administered orally in tablet or capsule form.
Patient information leafletÂ
Generic Name: bismuth subgallateÂ
Why do we use bismuth subgallate?Â
bismuth subgallate has been used as an antidiarrheal agent. It can help reduce the frequency and liquidity of stools by absorbing excess fluids and toxins. bismuth subgallate has been used to control and reduce foul odors. Â